Genetics and Epigenetics Key Drivers of Cancer Development

Sergio Caprio^*
*Correspondence: Sergio Caprio, Department of Biological, Chemical and Pharmaceutical Science and Technology (STEBICEF), University of Palermo, Palermo, Italy, Email:

Keywords

Cancer • Patients • Oncogenesis

Introduction

Genetics, the study of genes and their inheritance, plays a fundamental role in cancer development. Mutations in specific genes can disrupt cellular processes involved in growth regulation, DNA repair, and cell cycle control, predisposing cells to malignant transformation. The identification of cancerrelated genes, known as oncogenes and tumor suppressor genes, has significantly advanced our understanding of the genetic basis of cancer.

Oncogenes are genes that promote cell proliferation and survival when mutated or overexpressed. These genes typically encode proteins involved in signaling pathways that regulate cell growth, such as the Ras and Myc oncogenes. Mutations in oncogenes can lead to constitutive activation of these signaling pathways, driving uncontrolled cell proliferation characteristic of cancer.

Literature Review

Conversely, tumor suppressor genes act as guardians of the genome, inhibiting cell growth and promoting DNA repair mechanisms. Loss-of-function mutations in tumor suppressor genes, such as TP53 (p53) and PTEN, impair their ability to regulate cell cycle progression and DNA damage response, facilitating the accumulation of genetic alterations and progression towards malignancy.

Hereditary cancer syndromes, such as hereditary breast and ovarian cancer syndrome (caused by mutations in BRCA1 and BRCA2 genes) and familial adenomatous polyposis (caused by mutations in the APC gene) highlight the significant impact of genetic predisposition on cancer susceptibility [1]. In these cases, individuals inherit mutations that confer a higher risk of developing specific types of cancer, underscoring the importance of genetic testing and counseling in cancer prevention and early detection. While genetics provides insights into inherited cancer susceptibility, epigenetics delves into heritable changes in gene expression that do not involve alterations in the DNA sequence itself. Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA-mediated regulation, play critical roles in regulating gene expression patterns and cellular identity.

Aberrant epigenetic alterations contribute to cancer development by silencing tumor suppressor genes and activating oncogenes. Hypermethylation of CpG islands in the promoter regions of tumor suppressor genes can lead to transcriptional silencing, impairing their tumor-suppressive functions. Conversely, hypomethylation of oncogene promoters can result in their overexpression, promoting tumor growth and progression [2].

Discussion

Histone modifications, such as acetylation, methylation, and phosphorylation, modulate chromatin structure and accessibility, influencing gene transcription. Dysregulation of histone-modifying enzymes, such as histone deacetylases (HDACs) and histone methyltransferases (HMTs), can disrupt normal chromatin organization and contribute to cancer development by altering gene expression profiles.

Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), regulate gene expression at the post-transcriptional level and participate in various cellular processes, including proliferation, apoptosis, and metastasis. Dysregulated expression of miRNAs and lncRNAs has been implicated in cancer pathogenesis, with some serving as oncogenic drivers or tumor suppressors depending on their target genes and cellular context. The cancer epigenome refers to the global landscape of epigenetic alterations observed in cancer cells compared to their normal counterparts [3]. Comprehensive epigenomic studies have revealed widespread changes in DNA methylation patterns, histone modifications, and non-coding RNA expression profiles across different cancer types.

Cancer-specific DNA methylation signatures have been identified, offering potential biomarkers for cancer diagnosis, prognosis, and treatment response prediction. Moreover, histone modification patterns associated with transcriptional activation or repression can distinguish between cancer subtypes and correlate with clinical outcomes, highlighting their potential as prognostic markers [4]. Epigenetic therapy, targeting aberrant epigenetic alterations in cancer cells, has emerged as a promising approach to cancer treatment. DNMT inhibitors, such as azacitidine and decitabine, and HDAC inhibitors, including vorinostat and romidepsin, have been approved for the treatment of hematological malignancies and are being investigated in solid tumors. These epigenetic drugs exert anti-cancer effects by reversing epigenetic silencing of tumor suppressor genes and promoting cancer cell differentiation and apoptosis.

Cancer is characterized by intra-tumoral heterogeneity, wherein distinct subpopulations of cancer cells coexist within the same tumor. Epigenetic mechanisms contribute to cancer heterogeneity by regulating gene expression programs that influence cellular phenotypes and behaviors, such as stemness, differentiation, and metastatic potential.

Epigenetic plasticity enables cancer cells to adapt to changing microenvironmental cues and therapeutic pressures, contributing to tumor progression, metastasis, and treatment resistance. Epigenetic reprogramming processes, such as Epithelial-to-Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) plasticity, drive phenotypic changes that enhance cancer cell survival and dissemination [5,6].

Understanding the dynamic interplay between genetics and epigenetics in shaping cancer heterogeneity and evolution is essential for developing personalized therapeutic strategies that target specific vulnerabilities within heterogeneous tumor populations. Integrated multi-omics approaches, combining genomic, epigenomic, and transcriptomic profiling, offer valuable insights into the molecular underpinnings of cancer heterogeneity and may inform precision medicine interventions.

Conclusion

Genetics and epigenetics are key drivers of cancer development, influencing cellular processes that govern cell growth, differentiation, and survival. Advances in genomic and epigenomic technologies have deepened our understanding of the molecular mechanisms underlying cancer pathogenesis, paving the way for innovative diagnostic and therapeutic strategies. Integrating genetic and epigenetic insights into clinical practice holds promise for improving cancer prevention, early detection, and treatment outcomes in the era of precision oncology.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Hou, Chuanli, Liangyun Liu, Jiaoyan Ren and Min Huang, et al. "Structural characterization of two Hericium erinaceus polysaccharides and their protective effects on the alcohol-induced gastric mucosal injury." Food Chemistry 375 (2022): 131896.

   Google Scholar, Crossref, Indexed at

2. Sabaratnam, Vikineswary, Wong Kah-Hui, Murali Naidu and Pamela Rosie David. "Neuronal health–can culinary and medicinal mushrooms help?" J Trad Compl Med 3 (2013): 62-68.

   Google Scholar, Crossref, Indexed at

3. Luo, Yongli, Zhi Yang, L. I. Su and Juanjuan Shan, et al. "Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF-κB and JAK/STAT3 signaling in human hepatocellular carcinoma." Cancer Lett 375 (2016): 390-399.

   Google Scholar, Crossref, Indexed at

4. Trivedi, Sunny and Michelle Starz-Gaiano. "Drosophila Jak/STAT signaling: Regulation and relevance in human cancer and metastasis." Int J Mol Sci 19 (2018): 4056.

   Google Scholar, Crossref, Indexed at

5. Chen, Jia, Xingyu Wang, Jianlin Zhang and Jiawei Chang, et al. "Effects of the Wnt/β-Catenin Signaling Pathway on Proliferation and Apoptosis of Gastric Cancer Cells." Contr Med Mol Imag (2022).

   Google Scholar, Crossref, Indexed at

6. Ba, Mingchen, Hui Long, Zhaofei Yan and Shuai Wang, et al. "BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c‐MYC." J Cell Biochem 119 (2018): 973-982.

   Google Scholar, Crossref, Indexed at